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Abstract 
 
Background: Achieving optimal glycaemic control is a key clinical objective in 
diabetes management. The maintenance of near normal blood glucose levels is 
considered crucial in the prevention of the microvascular and macrovascular 
complications of diabetes mellitus (DM). Telephone support can be an integral part of 
good diabetes care and patients requiring such support are contacted by the Diabetes 
Specialist Nurse (DSN). These calls are time consuming and the effectiveness of this 
service had not been evaluated previously.  
 
Research Question: Does telephone consultation with the DSN improve 
glycaemic control? - A review of telephone contacts over two months and subsequent 
follow up for six months. 
 
Is there a relationship between the number and frequency of follow up consultations 
and improvement in glycaemic control? 
 
Research Design and Method: A retrospective review of the local diabetes data 
base was performed to review patients who had received DSN telephone calls for 
poor glycaemic control. Patients were identified from weekly phone call lists in 
September and October 2012. The following data was collected and analysed: 
glycosylated haemoglobin A1c (Hba1c), weight, alterations to insulin dose and oral 
agents, number of calls per patient and the time period the calls were made over at 
baseline and six months following telephone contact. 
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Results: Data is reported as median with range, unless otherwise stated. 108 patients 
were called over the two month period. Of the 108 patients 56 (51.9%) were male and 
52 (48.1%) were female. The mean age for males was 63.1±14.2 years and for 
females was 63.6±13.9years. 26 patients (24.1%) had type 1diabetes (T1DM) diabetes 
and 82 patients (75.9%) had type 2 diabetes (T2DM). Each patient had a median of 
five calls (range 1-27 calls) over a median of thirteen weeks (range 1-26 weeks). Nine 
patients were on oral hypoglycaemic agents (OHAs) only and 99 patients were on 
either insulin therapy alone or a combination of insulin and OHAs. HbA1c 
significantly improved from 78mmol/mol (43-140) to 72 mmol/mol (41-132) (9.3 
[6.1-15] to 8.7 [5.9-14.2]%) at six months, p=0.0001, for those patients on insulin, 
(analysed using Wilcoxon test), however there was no significant improvement in 
HbA1c, p=0.400, for those patients on OHA’s only.  
Conclusion: DSN telephone support to patients approximately every eighteen days 
over thirteen weeks significantly improved HbA1c at six month follow up. Longer 
follow up is required to determine if this reduction is sustained.  
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Chapter 1 
Introduction 
 
1. Introduction 
1.1. What is Diabetes? 
DM is defined as a chronic disease that occurs when the pancreas does not produce 
enough insulin, or when the body cannot effectively use the insulin it produces. 
Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes 
and over time leads to serious damage to many of the body's systems, especially the 
nerves and blood vessels (World Health Organisation [WHO], 2013). There are two 
main classification of DM. T1DM is an auto-immune disease resulting in the 
destruction of pancreatic β-cells, whereas T2DM is strongly associated with obesity 
and occurs as a result of failing pancreatic β-cell function, responsible for the 
production of insulin, often alongside insulin resistance (De Fronzo, 2009). DM in 
general causes a loss of the ability to maintain normoglycaemia through relative or 
absolute insulin deficiency. 
Achieving optimal glycaemic control is a key clinical objective in diabetes 
management (Nathan, Kuenen, Borg, Zheng, Scoenfeld & Heine, 2009). The 
maintenance of near normal blood glucose levels is crucial to the prevention of the 
microvascular complications of diabetes (Williams & Pickup, 2004). Both the 
Diabetes Control and Complications Trial (DCCT, 1998) and the Stockholm Diabetes 
Intervention Study ([SDIS], Reichard, Berglund, Britz, Cars, Nilson, & Rosenqvist 
1991) are in agreement with this and showed that intensive diabetes management 
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prevents and decreases the development and progression of the microvascular 
complications of T1DM. The ADVANCE study (Advanced Collaborative Group, 
2008) randomised 11,140 participants with T2DM to either intensive glycaemic 
control, using gliclazide and additional medications to achieve a target HbA1c ≤ 6.5% 
or standard arm which used any medication except gliclazide with a target HbA1c 
according to local guidelines. The VA Diabetes Trial ([VADT] Duckworth et al, 
2009) randomised 1,791 participants with T2DM uncontrolled on maximum OHAs or 
insulin therapy to either intensive glycaemic control HbA1c < 6.0% or standard 
glycaemic control HbA1c of at least 1.5% separation. Both studies used a treatment 
algorithm to titrate medications to achieve the desired outcomes. However in both 
studies there was no significant reduction in cardiovascular disease (CVD) in the 
intensively treated arm and infact the VADT study actually showed more CVD deaths 
in the intensive arm than in the standard arm, although this was not statistically 
significant. There was in an increase in the number of severe episodes of 
hypoglycaemia in both groups.  The studies concluded that shorted duration of T2DM 
without established atherosclerosis may benefit from intensive glycaemic control, but 
treatment needs to be individualised in those patients with long duration of DM, 
history of severe hypoglycaemia, advanced atherosclerosis and advanced age, to 
reduce the risk of severe hypoglycaemia, protentially leading to increased risk of 
CVD mortality. DSN titration of OHA’s allows for assessment of an individuals 
blood glucose monitoring (BGM) and reported hypoglycaemia more effectively than 
algorithm titration.  
 
There are many barriers to optimising DM treatment, especially insulin therapy, 
include hypoglycemia, weight gain, and suboptimal initiation and dose titration. 
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Epidemiologic studies and randomised controlled trials (RCT) have shown that the 
risk for hypoglycaemia is proportional to the achieved level of glycaemic control,  the 
closer the mean glucose or HbA1c level is to normal, the greater the risk (Cryer, 
2002). In patients with T2DM, those using insulin have the highest risk for 
hypoglycaemia (Leese, Wang, Broomhall, Kelly, Marsden, Morrison et al, 2003).  
 
1.2.  Diabetes Epidemiology 
DM is a condition of epidemic proportions with an estimated worldwide prevalence, 
in 2011, of 366 million, and a United Kingdom (UK) prevalence of 2.9               
million people (Quality and Outcome Framework [QOF], 2011). This figure is 
expected to rise to five million people in the UK by 2025 and 552 million people 
worldwide by 2030 (Diabetes UK, 2012). Of the people diagnosed with DM in the 
UK it is estimated that 90% are diagnosed with T2DM and 10% with T1DM.  
 
The 2011 Census data states that Wirral, where the study was conducted, has a 
population of 319,800 (Office for National Statistics, 2011), of whom 15,353 people 
are diagnosed with DM (Health and Social Care Information Centre, 2012). Patients 
with DM living in the most disadvantaged areas need further support to ensure they 
are able to improve their diabetic control (Wirral Primary Care Trust, 2007). T2DM is 
also more prevalent amongst certain social groups. The most disadvantaged in the UK 
population are two-and-a-half times more likely to have DM at any given age whilst 
complications of DM, such as CVD, cerebrovascular disease and nephropathy have 
been estimated as three and a half times higher in the lower socio economic groups 
(Weng, Coppin & Sonksen, 2002). There are persistently high levels of deprivation in 
the Northwest. The Index of Deprivation combines a range of economic, social and 
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housing indicators to provide the most comprehensive picture of deprivation. The 
Wirral remains 60th out of 326 on the Index of Multiple Deprivation 2010, with 
Liverpool being at position one as the most multiple deprived localities nationally 
(Department for Communities and Local Government, 2011). In February 2011 
Wirral had 18,335 people claiming out of work benefits in its most deprived areas, 
this is 35.7% of the working age population in this area which is over double the 
national average (Appendix 2 shows a map of the Wirral and its most deprived areas). 
 
The overall aim of DM care is to enable people to achieve a quality of life and life 
expectancy similar to that of the general population. In essence it is important to 
reduce the risk of complications associated with DM which can lead to increase 
morbidity and mortality. A good services providing DM prevention and management 
includes ensuring equitable access for vulnerable groups, such as those living in 
institutional care and those experiencing social deprivation, as well as for black and 
minority ethnic groups (Diabetes UK, 2005). Provision of resources need to ensure 
that individuals with the most need have access to appropriate, accessible health care. 
 
1.3. Cost of Diabetes 
The costs of dealing with the complications of DM, e.g. CVD including heart disease, 
cerebrovascular accidents (CVA), retinopathy which can lead to blindness, 
nephropathy which can lead to renal failure and amputations, vastly outweigh the 
costs of early intensive therapy. Early treatment results in better outcomes and lower 
costs for the National Health Service (NHS). Approximately £23.7 billion was spent 
on DM in the 2010/2011 financial year, which equates to approximately 10% of NHS 
resources, with the ratio of the cost of complications to the cost of treatment 
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exceeding three to one (Hex, Bartlett, Wright, Taylor & Varley, 2012). The figure is 
expected to rise to 17% of NHS resources by 2035/6 (Hex, Bartlett, Wright, Taylor & 
Varley, 2012). Using national data from the 2001 census and Wirral General 
Practitionner (GP) registered population data, it can be estimated that the cost of DM 
to the NHS in Wirral is over £7.4 million annually (Wirral Primary Care Trust, 2007). 
 
1.4. Provision of Services 
Traditionally DM services have been provided in both primary and secondary care 
settings, with GPs referring the most complex patients with DM into the hospital 
clinic. On April 1st 2013, Primary care trusts (PCTs), who used to commission most 
NHS services and controlled 80% of the NHS budget were abolished and replaced 
with clinical commissioning groups (CCGs). CCGs have taken on many of the 
functions of PCTs and in addition some functions previously undertaken by the 
Department of Health (DOH). CCGs commission most services, including planned 
hospital care and they can services from any provider that meets NHS standards and 
costs, which can be NHS hospitals, social enterprises, charities, or private sector 
providers. 
 
The provision of diabetes services is complex as care is provided by a wide range of 
professionals, including general practitioners (GPs) and other primary healthcare 
professionals and specialist diabetes teams, as well as people with diabetes and their 
carers. The achievement of good outcomes for people with diabetes is dependent on 
the provision of well-organised and coordinated diabetes services that draw on the 
knowledge and skills of health and social care professionals working across primary 
and secondary care (Diabetes UK, 2005). 
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According to Haddad and Chetty (2012), most diabetes management occurs outside 
the clinics yet patients look for healthcare providers for support and counselling. 
Unfortunately due to limitations in staffing and contracting arrangements counselling 
patients on diet, exercise and other important self-management behaviours is not 
accomplished as part of routine care. 
 
1.5. Telephone Support 
 
Patients require a great deal of support if they are to maintain good control. Finding 
systems to provide ongoing support and follow-up for patients remains a challenge. 
Telephone contact is possibly the most versatile, accessible and cheapest medium. Car 
and Sheikh (2003) suggest that telephone follow-up extends the support provided 
through the reinforcement of behaviors and by allowing further adjustments in 
therapy without the need for another clinic visit. 
 
1.6. Defining Variables 
The study involved patients who were all under the care of the local hospital DM 
clinic and needed contacted by a DSN, who was based in the hospital outpatients 
department. Contact was made via the telephone. Assessment of DM was made 
during the consultation using patients’ home BGM levels with overall glycaemic 
control being assessed prior to contact and six months after by measuring HbA1c. 
HbA1c was analysed using International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) values. The DCCT aligned values for HbA1c will also 
be reported in the results. Weight was recorded in kilograms, using SECA seat scales, 
which are calibrated on a yearly basis. 
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1.7. The Research Project 
The following retrospective study was designed to assess the effect of telephone 
contact by the DSN to improve HbA1c in patients requiring follow up from self -
referral or following a clinic referral. This report explores the reason for the telephone 
contact and the impact of the DSN in more detail and assesses the evidence for and 
against telephone follow up for improving glycaemic control. The report describes the 
methodology and presents results for the study with reference to the effect on 
glycaemic control, weight, alterations in treatment and the number and frequency of 
phone contacts.  
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Chapter 2 
Literature Review 
 
The following literature review investigates in more depth the impact DSNs have in 
improving glycaemic control in patient with DM and the issues surrounding managing 
patients with DM. Current developments in technology to assist management and 
facilitate access to BGM results will also be discussed.  
 
2.1. Glycaemic Targets in Diabetes 
The National Institute for Clinical Excellence ([NICE], 2009) recommend a target 
HbA1c of between 48mmol/mol (6.5%) and 58mmol/mol (7.5%) for individuals with 
DM. The results of the latest National Diabetes Audit 2010-2011 indicates that there 
is much need for improvement as only 6.9% of individuals with T1DM achieved 
HbA1c <48mmol/mol (6.5%), and only 28.3% achieved HbA1c ≤58mmol/mol 
(7.5%). The results were only slightly improved in patients with T2DM with 26.4% of 
individuals achieving a HbA1c <48mmol/mol (6.5%), and only 66.5% achieving a 
HbA1c ≤58mmol/mol (7.5%) (Health and Social Care Information Centre, 2012). 
DeVries, Snoek and Heine (2004) concur with this and suggest that around 25% of 
the adult T1DM population have persistently poor glycaemic control.  
 
Teoh, Home and Leiter (2011) suggest that targets must be individualised to maintain 
an appropriate balance between the benefits and risks associated with good glycaemic 
control. The Action to Control Cardiovascular Risk in Diabetes ([ACCORD], 2008) 
Trial are in agreement with this and recommended that although an appropriate 
HbA1c target is generally 53mmol/mol (7.0%) individualized glycemic targets may 
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be appropriate for some patients for instance those who are older, have longer 
duration of DM, have a history of severe hypoglycemia, exhibit advanced 
microvascular or macrovascular complications, or present with extensive 
comorbidities. It is therefore essential to discuss with the patient appropriate HbA1c 
targets, which are also achievable.  
 
Several studies have shown that good glucose control is associated with a decreased 
risk of microvascular and macrovascular complications (DCCT, 1993; Reichard, 
Nilsson & Rosenqvist, 1993; Malmberg, 1997 & The UK Prospective Diabetes Study 
[UKPDS], 1998). However many studies show that good glycaemic control is often 
difficult to achieve. In a review of 1641 patients records, in a primary care setting, 
Goudswaard, Stolk, Zuithoff and Rutten (2003) suggest that the worse metabolic 
control in those treated with either OHA or insulin indicates that current treatment 
regimens might be not sufficiently applied to reach the targets of care. The study 
found that fasting blood glucose (FBG) appeared to be a strong predictor of HbA1c, 
which underlines the usefulness of this simple test in daily DM care.  
 
The challenge remains to find systems to provide follow up and support for patients, 
which can facilitate titration of treatment. One of the most versatile, accessible and 
cheapest medium to maintain patient support and contact is the telephone. This allows 
for reinforcement of behaviours and adjustment of therapy, without the need for a 
further clinic appointment (Car & Sheikh, 2003). Wu, Forbes, Griffiths, Milligan and 
While (2010) acknowledge that there is evidence to suggest that patients are achieving 
better diabetes control, however patients require a great deal of support if they are to 
maintain good control. In a meta-analysis of controlled trials they concluded that 
Student No.294612703 
 
10 
 
telephone follow up targeting patients with the poorest control can have significant 
clinical benefit and that varying the intensity of the follow-up based on patient need 
appeared to deliver better outcomes. 
 
According to Thompson, Kozak and Sheps (1999) a common approach for the 
intervention arm of several studies is to provide regular telephone contact with 
diabetes nurse educators for advice about insulin adjustment. As part of a chronic 
disease management strategy, telephone services can improve outcomes (Weinberger, 
Tierney, Booher & Katz, 1989; Debusk et al, 1994), which leads to a decrease in 
treatment costs (Wasson, Gaudette, Whaley, Sauvigne, Baribeau & Welch, 1992).  
 
2.2. Guidelines in Diabetes 
NICE (2004) recommend that patients with T1DM should be provided with open-
access services on a walk-in and telephone-request basis during working hours and a 
helpline staffed by people with specific diabetes expertise should be provided on a 24-
hour basis. Diabetes UK, (2009) acknowledge that being able to discuss thoughts or 
ideas, or to ask for advice in times of doubt or difficulty was reported as contributing 
directly to the success of patients’ self-management. NICE (2008) produced 
guidelines for the management of T2DM suggesting that when starting insulin therapy 
a structured programme employing active insulin dose titration should be used. This 
should encompass, structured education, continuing telephone support, frequent self-
monitoring, dose titration to target, dietary understanding, management of 
hypoglycaemia, management of acute changes in plasma glucose control and support 
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from an appropriately trained and experienced healthcare professional. Patients often 
find it difficult to attend the clinic setting and although some of these activities require 
face to face contact, many can be achieve through none face to face contact. It is 
essential that access to information and healthcare professionals is provided for 
patients in a way that is convenient to the patient, whether that be phone contact, 
email or websites. 
 
Regular assessments of blood glucose levels and effective self-care may improve 
glycaemic control, thereby reducing the risk of complications from DM (DCCT, 
1993; UKPDS, 1998). Unfortunately, many patients fall short of targeted glucose 
levels because of problems obtaining treatment or inadequate self-care (Kurtz, 1990). 
In particular, low income patients with DM use fewer outpatient services and have 
more hospitalizations than those with higher incomes (Bindman et al., 1995). Since 
telephones are almost universally available (Anderson, Nelson & Wilson, 1998), 
clinicians and associated professionals can use them to conduct health status 
assessments and provide self-care education for patients who have difficulty attending 
outpatient care.  
 
2.3. Effectiveness of Diabetes Specialist Nurses 
Specialist nurses are defined as ’a registered nurse, who, after a significant period of 
experience in a specialised field and with additional nursing education, is authorised 
to practice as a specialist and be involved in clinical practice, consultation, teaching 
and research (Tang, 1993). DSNs were introduced approximately sixty years ago to 
support people with DM and their carers’ in the management on their condition 
(Gosden et al., 2009). The DSN is also trained to make adjustments to a patient’s 
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treatment regimen, for example insulin dosage. DSNs may also advise patients on the 
management of inter-current illnesses, in particular advising on diabetic treatments 
during other illnesses. This enables a broader approach to patient management.DSNs 
provide education and support services to people with DM in many health care 
systems. A key goal is helping enable people to self-manage their DM. However, in a 
meta-analysis of six trials Loveman, Royle and Waugh (2003) found no strong 
evidence of benefit of care from DSNs for adolescents and adults with DM. Although 
short-term benefits may be possible, this has not been shown to result in long-term 
improvements. People receiving care from DSNs do not appear to have improved 
health when compared with usual care in hospital clinics or primary care with no 
specialist nursing input. There were limitations with the meta-analysis as all the trials 
included in the analysis had different interventions. The authors recommended the 
need for RCTs. Although there was no improvement in glycaemic control, data for 
quality of life measures were not collected (Loveman, Royle & Waugh, 2009). 
 
Yong, Power and Gill (2002) studied forty three insulin-treated patients with HbA1c 
levels > 7.5% who were given dietary advice and insulin dose adjustment. Almost 
two-thirds (63%) of patients achieved improvement, however the ‘non-improver’ 
group (37%) showed a mean deterioration in HbA1c. They concluded that DSN 
intervention for poorly controlled insulin-treated diabetic patients is generally 
effective, but intervention may be best targeted to responsive patients.  
 
2.4. Shifting Diabetes Services 
Since the emergence of the Quality and Outcomes Framework ([QOF], 2004) there 
has been a trend to shift services for long-term conditions like DM out of hospitals 
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into primary care. This shift was also recommended by the White papers, Shifting the 
Balance of Power: The Next Steps (DOH, 2002) and Our health, our care, our say: a 
new direction for community services (DOH, 2006). The aim is to benefit people with 
long term conditions like DM by providing easily accessible services closer to home.  
 
According to Hill (2007) the effects of payment-by-results (PbR) will support this by 
encouraging the commissioning of cost effective services that meet the needs of the 
local population. However the Association of British Clinical Diabetologists 
([ABCD], 2012) are concerned and suggest that the PbR tariff, which placed a set cost 
for each clinical encounter, has created a perverse disincentive to seek a specialist 
assessment. As a result many people with DM are deprived of access to the specialist 
team. PbR is not an appropriate funding model for long term conditions such as DM, 
as it disrupts the seamless cross boundary care pathway which is the essence of 
success in a long term condition (ABCD, 2012). With such a large population of 
people with DM it is now increasingly accepted that primary care will provide the 
majority of routine clinical care for this group (Diabetes UK, 2005). In the long term, 
telemedicine could dramatically reduce the overall costs of health services because of 
its potential to allow a fundamental restructuring of the way health care is delivered. 
This would principally result from redistributing resources from the hospital 
environment into primary care. Providing more services in primary care and 
ultimately in patients’ homes could be considered to be the ultimate goal for health-
care delivery and in part this could be facilitated by telemedicine (Hjelm, 2005). 
There is good evidence that the use of telehealth improves the quality of DM home 
care, including improved self-monitoring and self-care, and better physiological 
control (Biermann, Dietrich & Standl, 2000). 
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2.5. Telemedicine in Health Care 
Telemedicine is a vast subject, but as yet there is limited data on the clinical 
effectiveness and cost-effectiveness of most telemedicine applications. For many 
years, the telephone has been extensively used by health professionals and patients for 
keeping in touch. This is widely viewed as an effective form of telemedicine (Hjelm, 
2005). According to a study by King et al, (2012) evidence suggests that what patients 
want from technology is real-time assistance with daily behavioural decision-making, 
ability to share information with their healthcare team, connections with others for 
support and choice.  
 
DM telecare involves patient transmission of self-monitored blood glucose and 
feedback (including support and advice) from a DM health professional (Montori et 
al., 2004). Although the use of older approaches (telephone, fax) is commonplace, 
telemedicine applications increasingly use the latest innovations in computer and 
network technologies and other equipment (Roine, Ohinmaa & Hailey, 2001). 
Advances in communications technology have increased the potential methods and 
speed by which health-care professionals and patients can communicate. These have 
led to improvements in communication through faster access to the health 
professional. This is more convenience for patients as it saves time from attending the 
health care setting and the cost of travel and parking. It also improves equity of access 
to care previously denied because of such factors as socioeconomic constraints, 
especially in countries in the developing world. 
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2.6. Studies using Direct Telephone Contact 
There have been many studies investigating the effect of direct phone contact between 
patients and the DSN. Thompson, Kozak & Sheps, (1999) studied forty six patients 
who were randomised to receive either standard care or to have regular telephone 
contact with a DM nurse educator for advice about adjustment of insulin therapy. 
Twenty three patients in the intervention group received individualised telephone 
contact on an average of three per week, lasting fifteen minutes over six months. 
Insulin adjustments were recommended during most calls. Twenty patients 
experienced 10% drop in HbA1c. 
 
Kim and Oh, (2003) performed a similar study using thirty six patients, twenty who 
were in the intervention group. The intervention, which consisted of continued 
education and reinforcement of diet, exercise, medication adjustment 
recommendations, as well as frequent self-monitoring of blood glucose levels, was 
administered through twice weekly phone contact for the first month and weekly 
contact for the next two months. Both studies showed a reduction in HbA1c in the 
intervention arm after six months and twelve respectively. However both studies 
acknowledge the limitations of the studies including the time issue of the telephone 
contact and the expense of using the DM nurse educator for the intervention. The cost 
of poor glycaemic control and the complications associated with poor control 
outweigh the limitations identified in the study.  
 
A study by Piette et al, (2000a) identified a cohort of 280 patients who were randomly 
assigned to usual care or to receive an intervention that consisted of usual care plus 
biweekly automated assessment and self-care education calls with telephone follow-
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up by a nurse educator. Outcomes measured at twelve months included survey-
reported self-care, perceived glycemic control, and symptoms, as well as HbA1c and 
serum glucose levels. The intervention group showed increased rate of glucose 
monitoring, foot inspections and weight monitoring and an improvement in HbA1c 
which was 0.3% lower than the control group. The intervention group also reported 
fewer incidences of acute complications, including hyperglycaemia and 
hypoglycaemia. These improvements were achieved with an average of less than six 
minutes per month of nurse-patient contact. The nurse was able to use time more 
judiciously, focusing on the patients who most needed assistance. 
 
In contrast a meta-analysis of RCTs on patients with T2DM conducted by Wu, Forbes, 
Griffiths, Milligan and While, (2010) contradicts the above studies suggesting that 
overall, telephone contact has a limited impact on glycaemic control. From a total of 
8389 studies screened, thirty sixwere selected for full assessment, which were reduced 
to just seven studies for the analysis. The other studies were excluded for a number of 
reasons insluding not being RCT design, multiple interventions not just telephone 
contact, T1DM patients included in the studies or telephone follow up was not the 
intervention component. From the studies analysed three studies showed that patients 
with the poorest control appeared to benefit the most from telephone follow-up 
(Young et al, 2005; Piette et al 2000b; Piette, Weinberger, Kraemer & McPhee, 2001). 
However it was acknowledged that telephone interventions may need to be more 
flexible in their design, so that they target patients with particular characteristics who 
may benefit from either a general regular contact or reminder to those who need more 
specialist support and intervention (Wu, Forbes, Griffiths, Milligan & While, 2010). It 
is essential that patients who are motivated and willing to make alterations to their 
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treatment are targeted for telephone contact so that the DSN / educator’s utilise their 
time in the most effective way. 
 
The landmark DCCT (1993) clearly proved the benefits of achieving and maintaining 
near-euglycemia in patients with T1DM. However, to achieve good control, follow-up 
was frequent, weekly phone contact and monthly visits. To applies these techniques to 
large populations would be both time consuming and expensive. 
 
2.7. Studies Using Indirect Telephone Contact  
  
2.7.1. Modem Transfer 
As well as studies using direct telephone contact many studies have looked at 
automated telephone contact modem transfer and helplines. In a RCT of thiery one 
patients examining telecare versus modem transmission in patients with T1DM on an 
intensive insulin regimen, but failing to achieve glycaemic control Montori et al, 
(2004) found telecare to have a small impact on glycemic control after six months.  
Intervention was in the form of glucometer transmission with feedback. There was a 
trend in enhanced adherence to self-monitoring, which was greater in the telecare 
group, and better glycemic control in both groups. The main difference in care 
delivery between the two groups was in the health professional’s time. The greater 
nurse feedback was associated with more insulin dose changes. 
 
2.7.2. Diabetes Helplines in Diabetes Management 
As well as contact with the DSN to facilitate diabetes management there are many 
other valuable resources to assist patients in self-management.  Barnett, Chumbler, 
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Vogel, Beyth, Quinn and Kobb (2006) studied 800 veterans with DM to assess 
healthcare use in those enrolled in a Department of Veterans Affairs (VA) Care 
Coordination Home Telehealth programme, compare o those who were not. Patients 
in the intervention group used this messaging device daily to answer scripted 
questions about their DM symptoms and health status. The program consisted of 
nurse care coordinators (registered nurses or advanced registered nurse practitioners) 
who used disease management protocols to manage treatment and to educate the 
veterans about their disease to prevent more costly interventions. Barnett et al (2006) 
observed lower HbA1c levels and fewer “work-in” primary care visits in their two-
year follow-up. In a separate study using a multi-pronged approach that included toll-
free help lines for patient questions and glucose reporting with telephone follow-up 
and intervention, Malone, Shilliday, Ives and Pignone (2007) reported significant 
improvements in HbA1c level, diabetes-related knowledge, and satisfaction among 
the intervention group. Algorithms were developed for the intervention and there was 
formalization of flow or follow-up with the addition of a trained, non-health care 
provider staff member to provide education and facilitate therapeutic intervention.  
The algorithms allowed for more aggressive treatment for patients. Structured 
programs allow for DM to be managed in any setting by members of the multi-
disciplinary team, not necessarily the doctor or the nurse. 
 
2.7.3. Automated Systems 
Telephone-supported DM care improves glycaemic control. However, such programs 
can be labour intensive and costly. Automated calling systems represent a pragmatic 
and inexpensive way to improve telephone care. Automated telephone disease 
management (ATDM) systems use specialised computer technology to deliver 
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messages and collect information from patients using their touch-tone keypad or 
voice-response technology.  
 
According to Piette, Weinberger, Kraemer and McPhee (2001) ATDM systems can 
augment telephone care by providing frequent monitoring and health education to 
large patient panels while allowing clinicians to focus attention on individuals who 
need it most. In a RCT of 272 individuals with DMs on OHAs patients in the 
intervention group, receiving ATDM showed a greater improvement in HbA1c 
compared to the control patients, receiving usual care, 72mmol/mol (8.7%) and 
77mmol/mol (9.2%), respectively. The ATDM patients used their touch-tone keypad 
to report information about their self-monitored blood glucose (SMBG) readings, 
other self-care activities, perceived glycemic control, symptoms, and use of guideline-
recommended medical care. The trial shows that ATDM can be used to successfully 
manage DM care as long as the messages and responses are reviewed to ensure any 
patients requiring further intervention are identified. 
 
2.8. Issues with Telemedicine 
Although telemedicine clearly has a wide range of potential benefits, it also has some 
disadvantages. Heinzelmann, Lugn and Kvedar (2005) identified several problems 
encountered by healthcare professionals while using telemedicine. These range from 
staff discomfort with new technology to those who are concerned that telemedicine 
threatens healthcare practice. The main drawbacks of telemedicine that can be 
envisaged are a breakdown in the relationship between health professional and 
patient, issues concerning the quality of health information and organizational and 
bureaucratic difficulties (Hjelm, 2005). According to Goold and Lipkin (1999) the 
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doctor/healthcare professional–patient relationship has been and remains a keystone 
of care. This relationship is often lost through the use of telemedicine as it often 
involves patient contacting helplines or automated systems for management of their 
DM, which might alter the fundamental relationships between patients and their 
health care professionals. 
 
Other issues that need to be addressed include legal and ethical concerns, human and 
cultural factors, such as resistance to change, lack of infrastructure, linguistic 
differences and illiteracy technical and organisational factors (Craig and Patterson, 
2006). Issues with colloquial terms and regional accents can often lead to 
misunderstanding of information given to patients. Layman (2003) and Briggs (2001) 
used the concept of non-maleficence to emphasize professional responsibility, for 
confidentiality, since the legal aspect of confidentiality focuses on the relationships 
between individuals involved in delivering care rather than on systems used. When 
telemedicine involves transmission of data for management of care it is essential to 
ensure that secure networks are used to protect confidentiality and privacy.  
2.9.  The research questions 
2.9.1. Aim of project 
The aim of the research was to evaluate the effectiveness of telephone consultation by 
the DSN in the management of patients with DM.  
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2.9.2.  Primary research question 
Is there an improvement in glycaemic control and weight following telephone follow 
up, in patients with DM, over a six month period? 
Is there a relationship between the number and frequency of follow up consultations 
and improvement in glycaemic control?  
Primary outcomes: HbA1c and Weight, Dose Adjustment of Insulin 
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Chapter 3 
Methods 
  
3.1. Study design  
 
The study design is a retrospective review of the local DM data base. The review 
aimed to examine whether telephone contact with patients from the DSNs affected 
biometric parameters. Information was collected using the hospital computer system 
Cerner. A contact list prints weekly to inform the DSNs which patients they need to 
contact. The lists were collected for a period of two months, which were the months 
of September and October 2012 inclusively. The patients’ demographics, blood 
results and vital signs are collected routinely at every clinic visits. Information 
regarding HbA1c, weight and total daily insulin dose (TDI) were recorded at baseline 
and the number of phone contacts, frequency of contacts, alteration to treatment and 
HbA1c and weight were recorded six months after the initial phone contact. Due to 
the complexity of DM a number of patients had previous contacts with the DSN prior 
to the data collection period, but the data was only recorded for the study period.  
 
3.2. Ethical approval  
Ethical approval was sought through the University of Chester, Faculty of Applied 
Sciences Ethics Committee and was granted 5th April 2013. (Appendix 3 show the 
Ethics Submission Form, and Appendix 4 shows the approval letter). Ethical approval 
was not required from the Wirral University NHS Foundation TrustResearch and 
Development Department as the study was a retrospective study of the current DM 
service (Appendix 5). Permission to undertake the study and use the patients recorded 
data was granted by the two DM Consultants (Appendix 6). 
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3.3.  Dependent variables  
The dependant variable was HbA1c measured using the local phlebotomy service and 
the hospital laboratory. Results were reported using IFCC (International Federation of 
Clinical Chemistry) units, although DCTT results will also be included in the results 
section. For several years, most laboratories in the UK reported HbA1c levels in 
DCCT aligned percentages, which allowed us to directly compare HbA1c values in 
our patients with those of the participants in studies such as the DCCT (1993) and the 
UKPDS (1998). The IFCC has established the “true” HbA1c concentrations in 
samples, and so this new IFCC standard has been recommended as the basis for 
standardising HbA1c values across the globe (Consensus Committee, 2007). Patients 
were weighed using SECA seat scales, which are calibrated on a yearly basis. Weight 
was recorded in kilograms (kg). 
3.4. Independent Variable 
The independent variable was number and frequency of telephone contact with the 
DSN. The phone contacts involved the DSN assessing SMBG and discussing 
treatment regimes. If patients reported elevated BGM the DSN would titrate OHAs or 
insulin doses, provided no risk of hypoglycaemia was evident. Education was also 
provided on issues such as diet, carbohydrate counting, weight management, 
treatment in illness and any issues surrounding injection technique or injection sites. 
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3.5.      Population and subjects  
3.5.1.  Sample size  
The target size was 100 patients, as it was estimated that this represented the 
number of patients telephoned over the two month period. A total of 113 
patients were actually contacted over the two month period, however only 108 
were included in the analysis as follow up data was not available for five of 
the patients, as three had died and two were lost to follow up having been 
discharged from the clinic.  
 
3.5.2. Population and recruitment  
The population consisted of T1DM andT2DM patients who were under the 
care of the Clatterbridge Diabetes Department, based at Wirral University 
NHS Foundation Trust. All subjects required further input from the DSN for a 
number of reasons. Patients either self-referred or were referred to the DSNs 
by the medical team following a clinic appointment or an inpatient stay. The 
sample included all the patients contacted within the two month time period. 
This is a representative sample as it reflects characteristics of the total 
population (Aparasu, 2011). 
 
3.6.      Eligibility criteria  
3.6.1. Inclusion criteria  
Patients were all over the age of 16, with no upper age limit.  
 
3.6.2.  Exclusion criteria  
Patients were excluded from the study if they had no six month follow up data. 
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 3.7.       Consent  
Individual patient consent was not sought for this retrospective study as it was a 
review of the current DM service. Participants’ data was collected for the study, in the 
form of HbA1c, weight, treatment regimens, however none of the information in the 
study is patient identifiable. By virtue of the fact that patients’ attend the hospital 
setting and have blood samples taken for the clinic visit they are giving implied 
consent to having their information on the hospital data base and for this information 
to be used for audit purposes. 
 
3.8.      Procedures 
Patients were entered into the study if they were contacted by the DSNs via the 
telephone within the two month recruitment period of September 2012 and October 
2012. Patients HbA1c and weight prior to the recruitment period was recorded. Patients 
then had their HbA1c and weight recorded six months after the recruitment period as 
part of their clinic visit. As well as these parameters the frequency of phone contacts, 
the number of weeks the calls were made over and the number of failed phone contacts 
were also recorded. Failed contacts were when the DSN attempted to contact the patient 
but was unable to directly speak to the patient, i.e. leaving an answer machine message 
or unable to leave a message or speaking to a relative who was unable to provide 
information to the nurse about glycaemic levels. In the original proposal for the 
research the duration of the phone contact was intended to be included, however a 
change in the computer system meant that this data is no longer recorded on the patients 
contact form so this was excluded in the data collection. Figure 1 shows a Flow Chart 
of the study procedures. 
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3.9.     Statistical analyses  
Analysis of the data was performed using IBM SPSS Statistics for Windows, Version 
19.0. Armonk, NY: IBM Corp. The Test for Normality was performed on all the data. 
Normality is tested to establish whether a set of observations are from a completely-
specified continuous distribution (Coakes & Steed, 2004). For sample sizes over 100 
Kolmogorov-Smirnov test of normality was used and for sample sizes less than 100 
Shapiro-Wilk was used (Coakes & Steed, 2007).  
 
Analysis of the data was performed on the total study population. The data was then 
split into two groups for further analysis. Group 1 was defined as patients on insulin 
alone or in combination with OHAs for their DM treatment and Group 2 was defined 
as patients on OHAs only. Normality was tested for the whole population group of 
108 patients, and then for Group 1 and Group 2.  
 
Parametric tests were used for some analysis when the sample was normally 
distributed. This included comparing alterations in individual’s weight at baseline and 
six months where the Paired Samples t-test was used (Williams & Wagg, 2004). Data 
was reported as mean and standard deviation (SD) when sample was normally 
distributed. For the analysis of HbA1c and insulin doses at baseline and six months 
assumption of normality was violated so the non-parametric test Wilcoxon Signed 
Ranks Test was used, with median and range being reported (Williams and Wragg, 
2004).  
 
To examine if there was a relationship between the number and frequency of calls and 
analterations inHbA1c and weight the test of correlation was performed. Assumption 
Student No.294612703 
 
27 
 
of normality was violated so Spearmans Rho was used to analyse the correlations 
(Williams & Wragg, 2004). 
 
The level of statistical significance (p-value) was set to <0.05.  For all tests an α-level 
of 0.05 (two-tailed) was considered statistically significant and confidence intervals of 
95% were used to interpret findings. Medians and interquartile ranges were calculated 
as these measures of central tendency and spread are less sensitive to the presence of 
outliers (Carling, 2000). 
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Figure 1 Flowchart of Study Procedures  
 
 
    Identify Patients Contacted via           
Telephone During  
September / October 2012 
 
Baseline Data for Weight, 
HbA1c, Diabetes Treatment and 
Reason for Contact Recorded 
 
Telephone Input Assessed      
including number of calls,        
frequency of calls, Failed calls 
And clinic visits 
 
Data collected 6 months 
following recruitment period 
for Weight, HbA1c 
 
 
Data Analysis using Statistics 
for Windows, Version 19.0. 
Armonk, NY: IBM Corp. 
 
    Do patients have 6 month 
follow up data 
 
 YES 
 
  Continue into study for data 
collection 
 
 
 NO 
 
         Excluded from the study    
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Chapter 4 
Results 
4.1. Subject Characteristics 
For the purpose of statistical analysis the patients who were taking insulin will be 
analysed separately from those on OHAs alone. The patients on insulin therapy or 
insulin therapy plus OHAs for their DM management will be referred to as Group 1 
and the patients on OHAs only will be referred to as Group 2.  
 
4.1.1.  Characteristics for All Patients 
A total of 113 patients were contacted during the two month time of September and 
October 2012, of whom 108 patients were eligible to be included in the study and 
have their data analysed. Of the 108 patients 56 (51.9%) were male and 52 (48.1%) 
were female. The mean age for males was 63.1±14.2 years and for females was 
63.6±13.9years. Out of the 108 patients 26 (24.1%) had T1DM and 82 (75.9%) had 
T2DM. Table 1 shows the Baseline demographic and biomedical characteristics for 
Total Study Population, Group 1 and Group 2. Weight results were missing for three 
of the patients in Group 1 as they were wheelchair bound and unable to get onto the 
scales.  
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Table 1 Baseline demographic and biomedical characteristics for Total Study 
Population, Group 1 and Group 2. (Values are median unless otherwise stated). 
Variable 
Total Group  
 
Group I 
 
Group 2 
 
Number of patients  
 
108 99 9 
Number of females  
 
49 (45%) 46 (46.5%) 3 (33.3%)  
Age (years)  
 
64 (22-85) 
 
64 (22-85) 74 (63-81) 
HbA1c (mmol/mol) 
 
74±18* 78 (43-140) 67 (39-107) 
HbA1c (%) 
 
8.9 9.3 (6.1-15) 8.3 (5.7-11.9) 
Total daily insulin dose 
(units) 
 
44 (0-190) 48 (4-190) N/A 
Weight (kg) 
 
87.9 
(44.5-143.3) 
89.7±18.1* 97.0±24.3* 
*Mean and SD reported 
 
4.2. Descriptive Results 
Patients were contacted by the DSNs for a number of reasons. Table 2 shows a break 
down of the reason for phone contact.  Patients were contact for follow up as a result 
of a clinic visit or self-referral in the form of patients phoning or dropping into the 
DSNs office for education, advice and titration of medication. Of the nine patients in 
Group 2, one patient was contacted after being given a new meter, three for poor 
glycaemic control, one for support follow a clinic visit, two after commencing 
exenatide and two to assess their blood glucose monitoring results following a clinic 
visit. Although the DSN was asked to contact the patients in Group 1 for a variety of 
reasons they all needed their insulin titrated to improve control or reducing to prevent 
hypoglycaemia.  
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Table 2 Reason for Phone Contact 
 Type of Diabetes 
 
R
ea
so
n 
fo
r 
co
nt
ac
t 
Insulin Titration 7 33 
Hypoglycaemia 6 9 
Illness 0 1 
Meter 1 1 
Poor Control 12 27 
Support and Contact 1 4 
Exenatide 0 3 
Blood Glucose Monitoring 0 2 
Hyperglycaemia 0 1 
 
 
 
4.3. Analysis 
 
4.3.1.  HbA1c 
 
HbA1c was analysed pre and post for all 108 patients. Normality was tested using the 
Kolmogorov-Smirnov (Coakes and Steed 2007). As the assumption of normality was 
violated, Wilcoxon’s signed rank test (Williams and Wragg, 2004). Analysis was then 
performed on Group 1 and Group 2. As the total numbers in both groups was less than 
100 normality was tested using Shapiro-Wilk and again the assumption of normality 
was violated, so the Wilcoxon’s signed rank test was used to analyse the data for both 
groups (Coakes and Steed, 2007). Median and range was reported for all the results. 
The results for HbA1c levels are reported using IFCC and DCCT values (see Table 
3). 
 
4.3.2. Weight 
Weight was analysed pre and post for all 108 patients. Normality was test using 
Kolmogorov-Smirnov and assumption of normality was violated (Coakes and Steed, 
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2007), so the Wilcoxon Test was performed (Williams and Wragg, 2004). Analysis 
was then performed on Group 1 and Group 2. Normality was tested using Shapiro-
Wilk for both groups and which indicated the sample was normally distributed 
(Coakes and Steed, 2007). The Paired T Test was then used to analyse the data 
(Williams and Wragg, 2004). Mean and SD were reported for the Paired t-test results 
for Group 1 and Group 2 (see Table 3).  
 
 4.3.3. Insulin Dose 
Insulin dose was analysed pre and post for Group 1 as none of the patients in Group 2 
were on insulin therapy for their diabetes. Normality was tested using Shapiro-Wilk 
and assumption of normality was violated (Coakes and Steed, 2007) therefore the 
Wilcoxon Ranks Sign test was used to analyse the data (Williams and Wragg, 2004). 
Descriptive statistics were reported as median and range. (See Table 3). 
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Table 3 Primary outcomes baseline through six months   (Values are 
median) 
 
Variable  Baseline  6 Months 
Difference 
within groups 
baseline to 6 
months 
HbA1c (mmol/mol) 
 
Total 
Group 
N=108 
76 (39-140) 72 (39-132) 
 
z=3.880 
p=0.0001** 
 
 
Group 1 
N=99 
78 (43-140) 72 (41-132) 
 
z=3.801 
p=0.001** 
 
 
Group 2 
N=9 
 
67 (39-107) 
 
64 (39-120) 
z=0.841 
p=0.400 
HbA1c (%) 
 
Total 
Group 
 
9.1 (5.7-15) 8.7 (5.7-14.2) 
z=3.880 
p=0.0001** 
Group 1 9.3 (6.1-15) 8.7 (5.9-14.2) 
 
z=3.801 
p=0.001** 
 
 Group 2 8.3 (5.7-11.9) 8.0 (5.7-13.1) 
z=0.841 
p=0.400 
Weight kg 
Total 
Group 
87.9 
 (44.5-143.3) 
88.3 
 (46.2-141.1) 
z=1.492 
p=0.136 
Group 1 89.7±18.1* 90.3±18.4* p=0.131 
Group 2 97.0±24.3* 94.7±23.7* p=0.02** 
Dose of Insulin 
(units) 
Total 
Group 
N/A N/A  
Group 1 48 (4-190) 54 (0-220) 
z=3.258 
p=0.001** 
 Group 2 N/A N/A  
 
*denotes normality meets so mean and standard deviation reported 
** denotes statistically significant result at α-level of 0.05 
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4.4. Correlation between HbA1c and Number and Frequency of 
Calls 
 
 4.4.1.  Correlation HbA1c and Number of Calls 
The median number of phone calls was 5 with a range of 1-27 calls within thesix 
month time period. Figure 2 shows the number of telephone calls over the six months. 
 
Figure 2 Graph of Number of Phone Calls over the Six Month Period 
 
 
Spearman’s Rho test was performed to see if there was any correlation between the 
number of phone calls and an alteration in HbA1c levels. The non-parametric test had 
to be used as the assumption of normality was violated.  Table  4 shows the results of 
Spearman’s Rho test indicating that there was a correlation  between improvement in 
HbA1c and the number of phone contacts made p=0.022. However when the r value 
is examined it can be seen that r=-.220, indicating that there is a low negative 
correlation between HbA1c and number of phone calls. The coefficient of 
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determination was calculated and this gave a result of 4.84% (Cohen and Holliday, 
1996). The correlation coefficient (r value) indicates to what degree correlation 
exsists. A level of zero indiscates there is no correlation and a level of -1 or +1 
indicates there is perfect correlation. Levels inbetween indicate that there is some 
degree of correlation but not perfect correlation (Sapsord & Jupp 2006) 
 
Table 4 Spearman’s Rho Correlation Results 
 
Correlation Sig (2-tailed) Correlation 
Coefficient 
Coefficient of 
Determination  
Number of Calls 
Vs 
HbA1c 
 
0.022* 
 
-.220 
 
4.8% 
Frequency of 
Calls (weeks) 
Vs 
HbA1c 
 
0.020* 
 
-.224 
 
5.0% 
Dose Adjustment 
Vs 
HbA1c 
 
0.032* 
 
-.216 
 
4.7% 
Dose Adjustment 
Vs 
Weight Change 
 
0.292 
 
.107 
 
1.1% 
Failed Contacts 
Vs 
Number of 
Contacts 
 
0.0001** 
 
.346 
 
12% 
*Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed)  
 
4.4.2. Correlation HbA1c and Frequency of Calls 
The median number of weeks the telephone calls were made over was 
thirteenweekswith a range of 1-26 weeks within the six month time period. Figure 4 
shows the frequency of calls in weeks over the six months. 
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Spearman’s Rho test was performed to see if there was any correlation between the 
frequency of phone calls and an alteration in HbA1c levels. The non-parametric test 
had to be used as normality was not achieved. Figure 5 shows the results of 
Spearman’s Rho test indicating that there was a correlation  between improvement in 
HbA1c and the frequency of phone contacts made p=0.02. However when the r value 
is examined it can be seen that r=-.224, indicating that there is a low negative 
correlation between HbA1c and number of phone calls. The coefficient of 
determination was calculated and this gave a result of 5.02% (Cohen & Holliday, 
1996) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Graph of Frequency of Calls in Weeks over the six month period 
 
Frequency of Calls in Weeks 
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4.4.3. Correlation between HbA1c and Dose Adjustment 
 
A Spearman’s Rho test for correlation was performed to see if there was any 
correlation between alterations in HbA1c and insulin dose adjustment. This was just 
performed for the patients in Group 1. The results (see Table 4) showed there was a 
correlation between HbA1c and dose adjustment p=0.032, however the r=-.216 value 
again indicated that there is a low negative correlation between HbA1c and insulin 
dose adjustment. The coefficient of determination was calculated and this gave a 
result of 4.67% (Cohen and Holliday, 1996). 
 
4.5. Failure to Contact 
 
During the six month study period the DSNs made many phone calls which resulted 
in no contact with the patient. This included speaking to relatives as patient 
unavailable, messages left on answer machines and the DSN being unable to leave 
any message to inform the patient they had been trying to contact the patient. The 
median number of fail to contact was one phone contact with a range of 0-7. The data 
was examined to see if there was any correlation between the number of phone 
contacts and the number of failed contacts. The assumption of normality was violated 
so Spearman’s Rho test of correlation was performed. The results (see Table 4) 
showed there was a correlation between number of phone contacts and number of 
failed contacts p=0.0001. However the r=-.346 value indicated that there is a low 
negative correlation between the number of contacts and the number of failed 
contacts.The coefficient of determination was calculated and this gave a result of 
11.97% (Cohen and Holliday, 1996). 
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Chapter 5 
Discussion 
5.1. Summary of Main Results 
The review was undertaken to determine the effectiveness of telephone consultation 
in the management of patients with DM. The data was collected from a total of 108 
patients. Although the majority of patients were contacted for insulin titration (n=99) 
patients were contacted for numerous other reasons (see Table 2).  
 
 5.1.1.  Insulin Treated Patients 
  5.1.1.1. HbA1c Results 
The results of the study indicate that after six month telephone contact with the DSN 
HbA1C significantly improved from 78mmol/mol (range 41-132 [9.3%, range 6.1-
15%]) to 72mmol/mol (range 41-132 [8.7%, range 5.9-14.2%]), p=0.001 in those 
patients requiring contact for poor control and insulin titration. Despite the significant 
improvement, in participants treated with insulin, HbA1c levels were still above the 
recommended target of 48mmol/mol (6.5%) to 58mmol/mol (7.5%), (NICE, 2009). 
 
In a RCT by Thompson, Kozak and Sheps (1999) forty six patients with HbA1c ≥ 
69mmol/mol (8.5%) were randomised to either regular telephone contact with a 
diabetes nurse educator for advice about adjustment of insulin therapy or to continue 
regular clinic visits. The telephone intervention group received approximately three 
calls weekly, lasting on average fifteen minutes. At six months mean HbA1c in the 
intervention group was 62mmol/mol (7.8%), compared with 74mmol/mol (8.9%) in 
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the standard care group, (p < 0.01). The telephone advice for the 23 patients in the 
intervention group took approximately seventeen hours per week of nursing time. 
This amount of input is not transferrable to large cohorts of patients. In the study the 
DSN only worked fifteen hours and had other responsibilities such as ward inpatients 
and DSN led clinics so frequency of calls were limited. 
 
According to Kennedy, Herman, Strange and Harris, (2006) the frequency of 
communicating insulin titration via clinical contact, telephone, e-mail, or fax is highly 
correlated with improvement of HbA1c levels. The GOAL A1C trial randomised 
7,893 patients with T2DM requiring insulin therapy to usual care, algorithm titration 
or active weekly titration. All groups showed an improvement in HbA1c. Patients in 
the usual titration groups had mean HbA1c reductions of 14mmol/mol (1.3%) from 
baseline to end point of twenty four weeks, whereas patients in the active titration 
groups achieved a mean reduction of 16mmol/mol (1.5%) (Kennedy, Herman, 
Strange & Harris, 2006). This is a greater reduction than seen in the study where the 
reduction in HbA1c was 6mmol/mol (0.6%). In addition to the phone contacts the 
GOAL A1c trial used a treatment algorithm in all groups to encourage insulin 
titration, which are a useful resource when DSN resources are limited. There are 
advantages to algorithms, however it is important that education is given in addition 
to ensure patients titrate safely and are aware when not to adjust their insulin. Less 
frequent contacts would be required if a treatment algorithm could be incorporated in 
conjunction with telephone contact follow up.  
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  5.1.1.2. Weight Results  
Weight gain is a major concern for patients on insulin therapy. The results of the 
study showed that in the patients treated with insulin the weight increased from 
89.7±18.1kg to 90.3±18.4kg but this increase was not significant (p=0.131). In 
T1DM, weight gain is often perceived as desirable as weight gain on commencing 
insulin is viewed as normalisation to previous weight (Russell-Jones & Khan, 2007). 
In the DCCT (1993) the intensive therapy arm gained an average of 5.1 kg, whereas 
the conventional arm gained 2.4 kg, after an average follow-up of 6.5 years. 
Approximately half the study population of the DCCT were recruited within the first 
five years of diagnosis, however the rest were recruited within fifteen years of 
diagnosis. This shows that the weight gain observed in the trial was not solely as a 
result of normalisation of body weight on initiation of insulin.  
 
The results of the study showed that in T1DM patients (n=26) in group 1 weight 
increased from a median of 84.1kg to 87kg, an increase of 2.9kg, however the T2DM 
patients (n=73) in group 1 showed a decrease in median weight from 89.7kg-88.7kg (-
1kg), after six months. The weight loss in the T2DM patients in Group 1 could have 
been as a result of the initiation of other agents. Three patients had metformin added 
to their insulin therapy and four patients had a Glucagon-like peptide-1 analogue 
(GLP analogue [see Appendix 7 for information]) added (n=1 Byetta and n=3 
Bydureon). All clinical studies examining the addition of a GLP-1 to insulin therapy 
in patients with T2DM have reported weight losses from baseline from -1.8 to -12.8 
kg (Holst & Vilsbøll, 2012).  
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The UKPDS (1998) of T2DM individuals showed that insulin associated weight gain 
was greater in patients receiving intensified intervention than that of conventional 
intervention, 5.1 vs. 3.7 kg, (p < 0.0001) during the first twelve months of therapy, 
but the mean weight of both groups increased to values beyond ideal. In a study of 
fourteen patients using MDI therapy, titration using an algorithm produced a lowering 
mean plasma glucose levels from 17.5 to 7.7 mmol/l (p < 0.001), but in just six 
months, mean weight gain was nearly nine kg (Henry, Gumbiner, Ditzler, Wallace, 
Lyon, & Glauber, 1993). Weight gain correlated directly with mean serum insulin 
level demonstrating that insulin therapy can be used to bring about dramatic 
improvements in glycaemic control, but with the penalty of significant, dose-related 
weight gain. 
 
A study by Ryan, Livingstone, Ducluzeau, Salle, Genaitay and Ritz, (2008) found that 
the mean weight gain of 1.8 kg in twent three T2DM patients during the first six 
months of insulin therapy was not accompanied by a change in glucosuria, resting 
energy expenditure, or physical activity. It was concluded that increased energy intake 
was the only plausible explanation for the observed weight increments. Weight gain is 
also thought to be proportional to the number of insulin injections, or the TDI dose 
(Yki-Järvinen, 2001; Yki-Järvinen & Ryysy, 1999). The results of the study showed 
there was no correlation between TDI dose and alteration in weight (p=0.92).  
 
5.1.1.3. Insulin Dose Change 
Results indicate that one of the participants’ insulin stopped during the six month 
follow up period. This patient had poor glycaemic control and stopped insulin 
themselves. As a result of this, their OHAs were titrated to try and improve control.  
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The results show there was a significant change in TDI dose from 48 units (range 4-
190) to 54 units (range 0-220), p=0.001. However despite the change in TDI it did not 
result in achieving a target HbA1c level. Insulin titration needs to be more aggressive 
to achieve target HbA1c levels. There are many reasons why this is not always 
feasible including hypoglycaemia and weight gain. 
 
Cryer (2002) found that iatrogenic hypoglycemia hampers tight glycemic control and 
is considered the limiting factor in DM management. In the ACCORD study, (2008) 
there was an increase rate of severe hypoglycaemia, requiring third party intervention, 
in the intensive group compared to standard care of 3.1% and 1% respectively. This is 
in agreement with the DCCT (1993), where based on the first 817 subjects who were 
enrolled, 216 subjects reported 714 episodes of severe hypoglycaemia of which 549 
(77%) occurred in intensively treated subjects. Severe hypoglycaemia occurred more 
often during sleep (55%) (DCCT Research Group, 1991).  The DCCT (1993) 
occurred prior to the introduction of analogue basal insulins. A meta-analysis by 
Rosenstock, Dailey, Massi-Benedetti, Fritsche, Lin and Salzman, (2005) of 2,304 
T2DM patients showed that the risk of severe hypoglycemia and severe nocturnal 
hypoglycemia were reduced with insulin glargine by 46% (P=0.0442) and 59% 
(P=0.0231), respectively. The risk reduction of hypoglycaemia is similar in T1DM 
patients as shown in a RCT by  Vague, et al (2003) who reported the risk of 
hypoglycemia was 22% lower with insulin detemir than with NPH insulin (P < 0.05) 
and 34% lower for nocturnal hypoglycemia (P < 0.005), in a sample of 448 
individuals. Insulin can therefore be more aggressively titrated when using the newer 
analogue insulins, to achieve target HbA1c. 
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In the study there was a significant correlation between improvement in HbA1c and 
dose adjustment of insulin (p=0.032). However this was a low negative correlation, r= 
0.216 which indicates that as the insulin dose increases the HbA1c decreases, but 
there is weak link between the correlation meaning that it might not be the dose 
increase which is causing the HbA1c to decrease. The co-efficient of determination 
was 4.7%, suggesting that there is only a 4.7% chance that the improvement in 
HbA1c was as a result of dose titration...  
 
 5.1.2. OHA Treated Patients 
  5.1.2.1.   HbA1c Results 
There was an improvement in HbA1c in group 2 which contained the patients on 
OHAs only, but this improvement was not significant (p=0.400), with HbA1c altering 
from 67mmol/mol (range 39-107mmol/mol [8.3%, range 5.7-11.9%]) at baseline to 
64mmol/mol (range 39-120mmol/mol [8.0%, range 5.7-13.1]) at six months. The 
numbers of individuals in this group was limited to just nine patients as patients on 
OHAs treatment alone tend to be managed in the Primary Care setting. The patients in 
this group were contacted for a number of reasons including assessment of BGM after 
being giving a replacement meter, for poor glycaemic control, to assess control and 
for support, for assessment of exenatide treatment and to assess BGM results. The 
majority of these patients needed to commence insulin due to their poor glycaemic 
control, however this did not occur during the six month follow up period as the 
patients wanted to be given the opportunity to improve their glycaemic control 
through lifestyle modification. 
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A RCT of 473 individuals with T2DM showed no significant change in HbA1c in the 
intervention group 64mmol/mol to 63mmol/mol (8.0% to 7.9%) compared to control 
65mmol/mol to 63mmol/mol (8.1% to 7.9%) at eighteen months (Blackberry et al, 
2013). The intervention was structured telephone coaching to prime patients with the 
aim of self managing their DM including lifestyle issues, medication adherence and 
dosing, self monitoring of their disease, and how to take greater initiative in the 
therapeutic alliance with the treating doctor, facilitating appropriate intensification of 
medications to achieve treatment goals. At baseline 74% of participants were taking 
oral medications only in the intervention group and 70% in the control group which 
decreased to 58% and 61% retrospectively at eighteen months. The RCT showed 
there was no improvement in HbA1c or intensification of insulin or other treatment 
methods. The intervention used practice nurse in the Primary care setting, who 
received a two day training session to deliver the telephone coaching sessions, 
whereas this study used DSNs who had ten years of experience adjusting insulin and 
other treatments and coaching patients on lifestyle issues. Both studies showed it is 
difficult to improve HbA1c in those patients on OHAs through telephone consultant 
and other methods such as education courses may be more beneficial. 
The ADVANCE study (2008) involved a protocol driven titration of OHAs and then 
insulin therapy if target HbA1c level was not achieved at each study visit. Mean 
HbA1c at the start of the study was 58mmol/mol (7.5%) which reduced to a mean 
level of 48mmol/mol (6.5%) and 56mmol/mol (7.3%) in the intervention group and 
standard care group respectively. The median follow up in the ADVANCE study was 
five years compared to six month in this study.  
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The time frame of this study was limited which did not enable titration of medication 
to achieve a significant improvement in HbA1c. Patients on OHA’s alone are often 
reluctant to titrate their medication or to commence insulin therapy so it often takes 
time for the DSN to develop a trusting relationship to facilitate this. Patients often 
delay the decision to commence insulin and opt for lifestyle modification before the 
inevitable happens and they require insulin therapy. 
A RCT by Young et al, (2005) showed a decrease in HbA1c, in patients with T2DM, 
following twelve months follow up in the intervention group of 0.3% from baseline. 
Intervention included telephone contact every one-three months for twenty minutes, 
to assess gaps in knowledge, patients readiness to change, medication adherence and 
BGM, The trial include 591 patients over 25 practices. The number of practices 
involve in the trial allowed the phone contact duration to be twenty minutes. 
 
In this study the telephone contact were made by two DSNs who work a total of 
twenty nine hours a week. Telephone contacts are just one aspect of their job 
description, in addition to inpatients, nurse led clinics, T1DM education class and 
patient drop in visits. This meant that the duration of telephone contact time and the 
frequency of phone contacts are limited due to time constraints in the DSNs working 
day. Longer duration of phone contact would have allowed for more education and 
advice regarding lifestyle issues, such as exercise, dietary intake and weight 
management.  
 
5.1.2.2. Weight Results 
Patients weight decreased significantly from 97.0±24.3kg to 94.7±23.7kg, (p=0.02). 
Except for two patients who required contact for assessment of BGM, all patients had 
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a weight loss of between 0.7kg-5.9kg. NICE guidelines, (2008) suggest that 
individuals with DM, who are overweight, should aim for an initial body weight loss 
of 5–10%, while remembering that lesser degrees of weight loss may still be of 
benefit and that larger degrees of weight loss in the longer term will have 
advantageous metabolic impact. 
 
Atherosclerotic cardiovascular disease is increased several fold in most patients with 
T2DM, particularly patients who are older and have other risk factors, including 
hypertension, obesity and dyslipidaemia (Stamler, Vaccaro, Neaton & Wentworth, 
1993). Weight loss can improve glucose control, as it has been associated with 
reduction in HbA1c, improvements in dyslipidemia and hypertension, and reduced 
mortality. Williamson, Thompson, Thun, Flanders, Pamuk and Byers (2000) found 
that in prospective analysis, with a twelve-year mortality follow-up of 4,970 
overweight individuals with T2DM intentional weight loss was associated with a 25% 
reduction in total mortality, and a 28% reduction in CVD and diabetes mortality. 
Intentional weight loss of 20-29 lb was associated with the largest reductions in 
mortality by approximately 33%. 
 
In contrast The Look AHEAD study, (2013) randomly assigned 5,145 participants 
with T2DM to either Intensive Lifestyle Management, (including enrolment in a 
weight management program providing individual and group support for changing 
eating behaviour and engaging in physical activity) or to the Support and Education 
group (receiving infrequent support on general health topics). It was stopped early 
after eleven years as it was concluded there was no difference in cardiovascular 
disease rate between the two groups, but other health benefits were achieved. The 
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intervention group had weight loss of 6% of their initial weight, 8.7 ± 7.6 kg versus 
3.5% for the control group, 0.8 ± 5.0 kg, at the study’s conclusion (Look AHEAD 
Research Group, 2013).  It appears that weight loss can reduce CVD and mortality, 
however weight loss needs to be significant, at least 20 pounds (lb).  
 
5.2. Frequency and Number of Contacts 
The median number of calls over the six month period was five calls (range 1-27 
calls) over thirteen weeks (range 1-26 weeks), which equates to a phone contact 
approximately every eighteen days. The frequency of contacts corresponds to studies 
by Glasgow and Toobert (2000); Piette et al (2000a) and Kirkman et al (1994), who 
contact particpiants biweekly or at least monthly. Kennedy, Herman, Strange, Harris 
and GOAL AIC Team, (2006) showed that active titration of insulin over a weekly 
period compared to ‘usual care’ or algorithm titration resulted in greater number of 
patients reaching target HbA1c <7.0%. Swinnen and DeVries (2009) found following 
a medline search that the frequency of both clinical and telephone contacts were 
independent predictors of HbA1c improvement and that the frequency of contact with 
the study team is highly correlated with the improvement in glycaemic control 
achieved after basal insulin initiation in T2DM.  
 
It is useful to know if there is any correlation between improvement in HbA1c and 
number of telephone calls or frequency of telephone contacts. The results showed 
there is a significant correlation between the number of calls and reduction in HbA1c 
(p=0.022), however this is a low negative correlation, meaning that the more phone 
contacts the patient received the greater the improvement in HbA1c. However it is 
impossible to report conclusively that this is the reason for the improvement in 
Student No.294612703 
 
48 
 
HbA1c. The coefficient of determination was 4.8%, indicating that there is a 4.8% 
probability that HbA1c improvement is as a result of the number of phone contacts. 
The results show that there was also a significant correlation between frequency of 
phone contacts and improvement in HbA1c, (p=0.020). Again this was a low negative 
correlation, r=-.224, which indicates that although there was a correlation, it is a low 
correlation meaning that it can not be reported conclusively that improvement in 
HbA1c was as a result of frequency of telephone contacts. The co-efficient of 
determination was 5%, suggesting that there is only a 5% chance of the improvement 
in HbA1c being as a result of the frequency of telephone contact.  
 
5.3. Failed to Contact 
The main problem with telephone contact is the number of failed to contact. The 
study showed a median of one fail to contact (range 0-7 fail to contact). Failed to 
contact included the DSN left messages on answer machines or with relatives but 
often were unable to leave any contact message for the participants, meaning time is 
often spent contact patients with no outcome. A total of 779 telephone contacts were 
made over the two month study period and out of these there was a total of 169 failed 
contacts (21.7%). Each attempted contact takes approximately five minutes, which 
means over the six month study period the DSN used approximately fourteen hours 
contacting patients with no clinical benefit. More efficient ways of working need to be 
introduced to reduce the wasted time. For instance those patients who are unable to 
return calls, due to working hours, or no answer machine service may need to use 
email contact or fax through BGM results. Protocol or algorithm titration guidelines 
may need to be developed to give patients, following their clinic visit, with phone 
contact on a monthly basis from the DSN to assess control. Patients are always 
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provided with contact details to enable them to access the DSN if required in-between 
planned contacts.  
 
5.4. Development of the Service 
Currently the DM service involves both clinic visits and telephone contact in both 
primary and secondary care. Telephone contact is one method of contacting patients, 
between clinic visits, to assess glycaemic control and titrate medication, however 
alternative methods of contact need to be assessed. Clinic visits to the secondary care 
outpatient service are an expensive resource with a clinic visit currently costing £225 
and £227 for an initial outpatient consultant led clinic appointment for a single 
professional and a multi professional contact respectively (Department of Health, 
2013). This cost is reduced to £101 for follow up attendance irrespective of whether it 
is a single or multi professional clinic. There is a recommendation of a £23 charge for 
non face-to-face outpatient contact but this is non mandatory tariff. The effectiveness 
of telephone contact in improvement HbA1c needs to be used to commission 
payments for the DSN telephone service as currently there is no payment attached to 
this service. Telephone contact is not only a more cost-effective resource compared to 
clinic visits it is also more convenient for the patients.  
 
Wirral is a borough of contrast and diversity in both its physical characteristics and 
social demographics. There are both rural areas and townships and urban and 
industrialised areas in a compact peninsula of 60 square miles. People with DM living 
in the most deprived areas of Wirral are significantly more likely to be admitted to 
hospital as an emergency case (Wirral NHS, 2012). Out of the 108 participants in the 
study 54 lived in the most deprived areas of the borough. Figure 4 shows a graph of 
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patient distribution by postcode within the Wirral area and Appendix 2 shows a map 
of the Wirral with a breakdown of the postcode areas and the areas of deprivation 
corresponding to these postcodes. Clatterbridge Hospital is set in a rural area and has 
a limited public transport link. Patients often find difficulty getting to the hospital and 
if using public transport they often have to use more than one bus and if they drive to 
the hospital there is an additional charge for car parking. This is an expense which can 
be avoided through providing a DSN phone service. 
 
Figure 4 Patient Distribution by Postcode on the Wirral 
 
5.5.  Strengths of the Study 
The study was a retrospective review of the current DM service. This allowed for a 
review of the current service without any investigator bias. If the study design had 
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been a prospective review the investigator may have been more inclined to titrated 
treatment more aggressively. Data were handled sensitively taking sample size, 
skewed variables and outliers into consideration through the use of non-parametric 
tests, and medians and interquartile ranges as measures of centrality and dispersion. 
As the study design was a retrospective review of the data base participants were 
unaware they were part of a review. Many studies have shown an improvement in 
HbA1c whilst the patient are in contact with the study nurse however this often 
disappears when the contact has finished. This is referred to as the “Hawthorne 
Effect”. This stems from the observation that people alter their behavior when they 
know that this is being studied, in ways that may influence study outcomes. This has 
implications for the conduct of clinical trials, which should allow for the likelihood 
that HbA1c will already be falling in most participants by the time any other 
intervention is introduced (Gale, Beattie, Hu, Koivisto & Tan, 2007). 
 
5.6. Limitations of the Study 
There weresome limitation to the study design. The sample size was limited due to the 
time constraints to allow for the six month follow up and to manage the time frame of 
the Master Programme. The results showed an improvement after six months, but it 
would be beneficial to see if this improvement continues after twelve months and then 
two years.  
 
There was no data collected for psychological well-being and satisfaction scores 
associated with contact with the DSN. Although it is important to improve patients 
glycaemic control, often it is necessary to improve patients psychological wellbeing 
through DSN support before you can begin to titrate their treatment.  
Student No.294612703 
 
52 
 
As well as the patients satisfaction questionnaires other data was not collected 
including the length of diagnosis of DM and insulin regime, whether it was basal 
insulin, twice daily insulin or a basal bolus regime, as this may have made a 
difference to the aggrresiveness of insulin titration.  
 
5.7. Future Research 
The study has given an overview of the current DM telephone service being provided 
by the DSNs. The study design was a retrospective review which meant thst the DSN 
was unable to record some of the data as it was missing. A RCT would provide more 
robust data and enable the essential data to be collected. Information on patients’ 
satisfaction of the DSN contact service and patients well-being scores would be useful 
to collect.  
 
There was no structure to the telephone consultation in this study so further studies 
would benefit from a protocol drive telephone consultation to ensure all aspects of 
diabetes care are covered. Treat to target algorithms should be incorporated into 
future studies to ensure treatment is titrated aggressively. 
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Chapter 6 
Conclusion 
The research question asked whether telephone consultation with the DSN improves 
glycaemic control, and whether there was a relationship between the number and 
frequency of follow up consultations and improvement in glycaemic control? 
 
The study showed that there was an improvement in HbA1c, following contact by the 
DSN over a duration of six months, however target HbA1c was not achieved. 
Improvement in HbA1c is often dependant on patients’ willingness to make changes 
to their treatment. Patients build a relationship of trust with their DSN which enable 
treatment titration, however issues with acute complications associated with diabetes 
such as hypoglycaemia often prevent patients achieving glycaemic control.  
 
Despite there being a significant correlation between improvement in HbA1c and 
telephone contacts, the correlation was weak so it can not be inferred that the 
improvement was a result of number of calls or the frequency of calls.  
 
DSNs use telephone contacts to manage patients’ diabetes on a daily basis, 
unfortunately message are left which aren’t always returned or no contact is achieved. 
More efficient methods of contact need to be developed to enable assessment and 
alterations of patients’ treatment 
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Appendix 7 – Information on GLP-1 Mimetics 
This class of drug includes:- 
Byetta 
Bydureon 
Liraglutide 
Lixisenatide 
Endogenous GLP-1 is secreted in anticipation of a meal and in response to ingested 
glucose in order to potentiate endogenous glucose-stimulated insulin secretion. In 
terms of diabetes management, native GLP-1 has been considered for the treatment of 
T2DM (Gutniak, Linde, Holst, Efendic, 1994). However, its half-life after 
subcutaneous injection is only 1.5–3 min in humans (Vilsboll, Agerso, Krarup & 
Holst, 2003). Several long-acting GLP-1 mimetics have been developed to overcome 
this limitation, including exenatide and liraglutide as well as others currently under 
development. GLP-1 mimetics, which target postprandial glucose, should 
complement the activity of basal insulins, which are typically titrated based on fasting 
glucose levels. The GLP-1 mimetics that are either approved or in development have 
varying abilities to replicate the strong prandial effect of endogenous GLP-1. 
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Mode of Action of GLP-Mimetic 
 
 
 
 
 
 
